Risk Factors Related to New-Onset Diabetes after Renal Transplantation in Patients of a High Complexity University Hospital in Colombia, 20 Years of Experience
Table 2
Risk factors for NODAT in patients with renal transplantation between 1995 and 2014.
Characteristics
Total (n = 366)
Controls (n = 244)
Cases (n = 122)
value
Steroid treatment, n (%)
350 (96)
230 (94)
120 (98)
0.071
Treatment with tacrolimus, n (%)
148 (40.4)
103 (42)
45 (36)
0.328
Treatment with mTOR inhibitor, n (%)
59 (16)
33 (13)
26 (21)
0.056
CMV infection, n (%)
46 (12.5)
25 (10.25)
21 (17.2)
0.058
Prophylaxis for CMV, n (%)
100 (27)
67 (27)
33 (27)
0.934
Retransplant, n (%)
30 (8)
22 (9)
8 (6)
0.419
NODAT : new-onset diabetes after transplantation; mTOR inhibitor: mammalian target of rapamycin inhibitor; CMV: cytomegalovirus.
